STRO250117P5000
- 0.00
- 0.000.00%
Sutro Biopharma Newsroom
Sutro Biopharma Is Maintained at Equal-Weight by Wells Fargo
Sutro Biopharma Price Target Cut to $4.00/Share From $5.00 by Wells Fargo
Sutro Biopharma Analyst Ratings
TD Cowen Maintains Sutro Biopharma(STRO.US) With Buy Rating
Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $4 to $17
TD Cowen Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
Cautious Hold Rating on Sutro Biopharma Amid Mixed Luvelta Outlook and Delayed Timeline
Strong Buy Rating for Sutro Biopharma Amid Promising Trial Results and Strategic Financial Position
Piper Sandler Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $11
H.C. Wainwright Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $12
Sutro Biopharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $5 to $17
Sutro Biopharma: Hold Rating Amidst Uncertain Catalysts and Funding Concerns
TD Cowen Maintains Sutro Biopharma(STRO.US) With Buy Rating
Piper Sandler Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $11
Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $8 to $17